Jacques-P. Tremblay
Chercheur universitaire
Axe Neurosciences
Thérapie génique et moléculaire
Biotechnologies médicales
Publications
Voir tout-
article Siddika A, Husseiny FE, Rousseau J, Tremblay JP
Prime Editing Mediated Generation and Correction of the mdx5cv Mutation Restores Dystrophin Expression in Myoblasts
Int J Mol Sci 27 (15), 2026.
-
article Iwe IA, Liu FX, Corsano A, da Silva SJR, Doucet J, Singh S, Lamothe G, Zayani R, Nguyen J, Matthews Q, Vigar JRJ, Bayat P, Simchi M, Bozovicar K, Charania M, Panfilov S, Kelly P, Cai R, Hubbard BP, Li X, Mazzulli T, Tremblay JP, Zhao Y, Green AA, Li Z, Yao S, Pardee K
RAPID: evaluation of Cas12a protospacer nicking and chimeric reporters for PAM-independent RNA and DNA diagnostics
Nucleic Acids Res 54 (14), 2026.
-
article Siddika A, Rousseau J, Veillette F, Bouchard C, Lu Y, Tremblay JP
Gene Editing Strategies for Duchenne Muscular Dystrophy: From Molecular Mechanisms to Clinical Translation
Cells 15 (10), 2026.
Projets
- In vivo correction by CRISPR PRIME editing of mutations responsible for Duchenne Muscular Dystrophy, du 2023-12-01 au 2026-11-30
- Correction by Prime editing of point mutations responsible for Cystic fibrosis in Quebec province, du 2025-10-03 au 2028-03-31
- Development of a Prime Editing-Based Therapy for Alzheimer’s Disease, du 2026-01-01 au 2029-01-31
- Modification par Prime editing du gène MYOC pour prévenir le développement du glaucome héréditaire, du 2025-10-01 au 2026-09-30
- Correction par Prime Editing des Mutations Ponctuelles Responsables de l'ARSACS, du 2026-08-01 au 2027-07-31
- Removal of the GAA repeat with the CRISPR/Cas9 system in Friedreich patient cells and in the YG8sR mouse model, du 2019-10-01 au 2024-09-30
- Development of a rapid and simple test to detect the COVID-19 variants that can be used in remote areas and developing countries, du 2021-06-01 au 2025-03-31
- Development of an AAV library, du 2022-04-01 au 2024-09-30
- Correcting point mutations responsible for Dysferlinopathy using Prime Editing, du 2023-08-01 au 2025-01-31
- Développement d'un traitement pour prévenir ou ralentir la progression de la maladie d'Alzheimer, du 2023-11-08 au 2026-04-30
- Correction of point mutations responsible for Dysferlinopathy using Prime Editing Renouvellement 2025-2026, du 2025-02-01 au 2026-08-31